These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 15144573)

  • 1. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus.
    Corona Gutierrez CM; Tinoco A; Navarro T; Contreras ML; Cortes RR; Calzado P; Reyes L; Posternak R; Morosoli G; Verde ML; Rosales R
    Hum Gene Ther; 2004 May; 15(5):421-31. PubMed ID: 15144573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.
    García-Hernández E; González-Sánchez JL; Andrade-Manzano A; Contreras ML; Padilla S; Guzmán CC; Jiménez R; Reyes L; Morosoli G; Verde ML; Rosales R
    Cancer Gene Ther; 2006 Jun; 13(6):592-7. PubMed ID: 16456551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study.
    Albarran Y Carvajal A; de la Garza A; Cruz Quiroz BJ; Vazquez Zea E; Díaz Estrada I; Mendez Fuentez E; López Contreras M; Andrade-Manzano A; Padilla S; Varela AR; Rosales R
    BioDrugs; 2007; 21(1):47-59. PubMed ID: 17263589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.
    Rosales R; López-Contreras M; Rosales C; Magallanes-Molina JR; Gonzalez-Vergara R; Arroyo-Cazarez JM; Ricardez-Arenas A; Del Follo-Valencia A; Padilla-Arriaga S; Guerrero MV; Pirez MA; Arellano-Fiore C; Villarreal F
    Hum Gene Ther; 2014 Dec; 25(12):1035-49. PubMed ID: 25275724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
    Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
    Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p16
    Badiga S; Chambers MM; Huh W; Eltoum IA; Piyathilake CJ
    Cancer; 2016 Dec; 122(23):3615-3623. PubMed ID: 27479745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
    Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
    Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
    Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
    Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade.
    Hudelist G; Manavi M; Pischinger KI; Watkins-Riedel T; Singer CF; Kubista E; Czerwenka KF
    Gynecol Oncol; 2004 Mar; 92(3):873-80. PubMed ID: 14984955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.
    Rodríguez AC; Schiffman M; Herrero R; Hildesheim A; Bratti C; Sherman ME; Solomon D; Guillén D; Alfaro M; Morales J; Hutchinson M; Katki H; Cheung L; Wacholder S; Burk RD
    J Natl Cancer Inst; 2010 Mar; 102(5):315-24. PubMed ID: 20157096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
    Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
    Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears.
    Shlay JC; Dunn T; Byers T; Barón AE; Douglas JM
    Obstet Gynecol; 2000 Sep; 96(3):410-6. PubMed ID: 10960635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa.
    Marais D; Rose RC; Williamson AL
    J Med Virol; 1997 Feb; 51(2):126-31. PubMed ID: 9021543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities?
    Fait G; Daniel Y; Kupferminc MJ; Lessing JB; Niv J; Bar-Am A
    Gynecol Oncol; 1998 Sep; 70(3):319-22. PubMed ID: 9790781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women.
    Hernández-Hernández DM; Ornelas-Bernal L; Guido-Jiménez M; Apresa-Garcia T; Alvarado-Cabrero I; Salcedo-Vargas M; Mohar-Betancourt A; Garcia-Carranca A
    Gynecol Oncol; 2003 Aug; 90(2):310-7. PubMed ID: 12893192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
    Kann H; Hortlund M; Eklund C; Dillner J; Faust H
    Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.
    de Gruijl TD; Bontkes HJ; Walboomers JM; Schiller JT; Stukart MJ; Groot BS; Chabaud MM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    J Natl Cancer Inst; 1997 May; 89(9):630-8. PubMed ID: 9150187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.
    Sellors JW; Lorincz AT; Mahony JB; Mielzynska I; Lytwyn A; Roth P; Howard M; Chong S; Daya D; Chapman W; Chernesky M
    CMAJ; 2000 Sep; 163(5):513-8. PubMed ID: 11006761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
    Rambout L; Hopkins L; Hutton B; Fergusson D
    CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.